Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

LogicBio Therapeutics

LogicBio Therapeutics
2014 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
LOGC STOCK SYMBOL
$10.12 SHARE PRICE (As of Tuesday Closing)
Description

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 610 Main Street
  • 3rd Floor
  • Cambridge, MA 02139
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore LogicBio Therapeutics’s full profile, request a free trial.

LogicBio Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$6.34 - $20.07 $229M $10.07 -$1.83 27.5K 22.7M

LogicBio Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 221,091 250,817
Revenue 0 0 0
EBITDA (30,506) (18,013) (5,744) (3,393)
Net Income (29,475) (17,621) (5,795) (3,428)
Total Assets 68,030 82,910 26,174 2,029
Total Debt 967
Public Fundamental Data provided by Morningstar, Inc. disclaimer

LogicBio Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore LogicBio Therapeutics‘s full profile, request access.

Request full access to PitchBook

LogicBio Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore LogicBio Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

LogicBio Therapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avrobio Formerly VC-backed Cambridge, MA 00 00000 00000000000 00000
00000000 000000000 Formerly VC-backed Cambridge, MA 000 0000 000000000 0000
00000000000 000000 Formerly VC-backed Abingdon, United Kingdom 000 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed New York, NY 00 00000 00000000 00000
00000000 Formerly VC-backed London, United Kingdom 000 00000 000000000 00000
To view this company’s complete list of competitors, request access »

LogicBio Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore LogicBio Therapeutics‘s full profile, request access.

Request full access to PitchBook

LogicBio Therapeutics Executive Team (6)

Name Title Board
Seat
Contact
Info
Frederic Chereau Chief Executive Officer, President & Board Member
Matthias Jaffe Chief Financial Officer
Tom Wilton Executive
Adi Barzel Ph.D Co-Founder
Nelson Chau Ph.D Vice President of Biology & Translational Research

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

LogicBio Therapeutics Board Members (9)

Name Representing Role Since Contact
Info
Erez Chimovits LogicBio Therapeutics Board Member 000 0000
Frederic Chereau LogicBio Therapeutics Chief Executive Officer, President & Board Member 000 0000
Leon Chen Ph.D OrbiMed Board Member 000 0000
Leszek Lisowski LogicBio Therapeutics Co-Founder & Board Member 000 0000
Mark Kay MD LogicBio Therapeutics Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »